I've obtained some RNASeq data thats been TPM corrected for a cancer of interest from the CCLE (primarily interested in AML). How does one traditionally compare the TPM expression of an arbitrary gene in a cancer vs control? The CCLE doesn't seem to provide any control/baseline data so it's hard to know if your gene of interest is really at all overexpressed from the CCLE standpoint.
•
written
by
Dirk
1 answer
In such a scenario, we could go by Z-scores, whereby Z > 1.96 or Z < -1.96 are statistically significantly up- and down-regulated, respectively, at 5% alpha. Prior to Z-score transformation, in this case, it may make more sense to only have AML cell-lines in your dataset - if you have all other cell-lines, then the result and meaning / interpretation will change.
Kevin
Log in to answer this question.
-
TMM normalized TPM
written by firestar
-
Paired sample RNA-seq dataset analysis
written by pedram •
-
RNAseq datasets, TPM/FPKM/DE analysis questions
written by kitz.alexandra •
-
creating box plot from DESeq2 result
written by aswanikrishnap1994 •
-
Gene enrichment or rescue dataset
written by Dirk
-
Comparing gene expression of specific genes between samples in DESeq2 / R
written by masicioglu •
-
De Novo pathway generation
written by Dirk
-
Example of processed RNASeq datasets
written by Dirk
-
edgeR RNA-seq Results Across Conditions
written by asyndeton17 •
-
compare gene count profiles between samples
written by Abdullah
I'm not sure how helpful this is, but you can try going through the cell lines on atcc.org. AML is a little tricky, but for other cancer types, they have corresponding normal cell lines per tissue type available here. Once you get the names of the cell lines, go to either GEO or SRA to search for the data. You will probably will need to quantify the gene expression yourself.